Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival - Woodford - 2022 - Cancer - Wiley Online Library
Progression-free survival and overall survival probabilities. | Download Scientific Diagram
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Progression free survival and overall survival in patients treated with... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
A) Disease-free survival, (B) progression-free survival and (C)... | Download Scientific Diagram
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials | Haematologica
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis - The
Progression-free survival and overall survival in all patients. | Download Scientific Diagram
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression-free survival as a surrogate endpoint of overall survival | OTT
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
Understanding Overall Survival in Metastatic Breast Cancer
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
Extrapolation from Progression Free Survival to Overall Survival in O…
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
